Tabalumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | BAFF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146252.08 g·mol−1 |
  (what is this?) (verify) | |
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2][3] Tabalumab was developed by Eli Lilly and Company.
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[4] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[5]
Now dropped by Lilly due to lack of efficacy.
References
[edit]- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
- ^ "BAFF Antibody: Tabalumab, LY2127399". Lilly USA, LLC. Archived from the original on 12 August 2013.
- ^ Ward P, Bodmer M (September 2014). "Antibodies in Phase III Studies for Immunological Disorders.". In Dübel S, Reichert JM (eds.). Handbook of Therapeutic Antibodies. pp. 851–926 (899). doi:10.1002/9783527682423.ch29. ISBN 978-3-527-68242-3.
- ^ "Press Release Archive - Press Release Archives".
- ^ "Lilly Halts Tabalumab Development for Lupus". 2 October 2014.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |